Ono Pharmaceutical Co., Ltd. OPHLY OTC · Healthcare · Japan
$5.01 -0.99% -$0.05
Summary
69 / 100 · Bulios Score
What speaks for it
- Out of every 100 JPY of revenue, 15 JPY is left as net profit.
- It holds more cash than debt: ¥259.8B against ¥110.7B.
- The share price is below the Bulios Fair Price.
What to watch
- Analysts expect revenue to fall by 15% this fiscal year.
- Earnings per share fell by 12% a year over the last 3 years.
- It missed profit estimates 4 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 15.0 JPY for 1 JPY of yearly profit. Over the last five years it was 26.4 JPY on average.
Valuation in detailIs it growing?
It is shrinkingRevenue (JPY)
Diluted EPS (JPY)
- Analyst estimate
Revenue grew by 12% a year over 5 years. Over the last 3 years it grew by 6.9% a year. For the next fiscal year analysts expect revenue to fall by 15%. Earnings per share fell by 12% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 JPY of revenue goes
- Cost of sales 26 JPY
- Research and development 30 JPY
- Sales and administration 22 JPY
- Taxes and other 6.9 JPY
- Net profit 15 JPY
Net profit, industry median (Drug Manufacturers - General) 14 JPY
Out of every 100 JPY of revenue, 15 JPY is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
High, at risk- Yield
- 6.68%
- Paid out of profit
- 100%
You receive $0.33 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
Mildly negative- Buy 0
- Hold 0
- Sell 2
No analyst has published a price target.
0.0% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.